LEXINGTON, KY, UNITED STATES, March 11, 2026 / EINPresswire.com / — The Child Neurology Foundation (CNF) today announced Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), ...
Tempus AI's diagnostics arm is surging in 2025 as precision oncology testing, MRD adoption, AI-driven genomic tools and the Ambry Genetics acquisition expand capabilities.
Funded Genomics Programs, and Rapid Adoption of NGS-Based Diagnostics Accelerate Global Genomics Services Market Growth.Austin, United States, March 05, 2026 (GLOBE NEWSWIRE) -- Genomics Services ...
On February 13, 2026, a putative class filed a Complaint in the U.S. District Court for the Northern District of Illinois alleging that Tempus AI, Inc. (“Tempus AI ...
Health care technology company Tempus AI was hit with a genetic privacy class action on Feb. 13 in Illinois Northern District Court. The complaint centers on Tempus AI's February 2025 acquisition of ...
Florida state Rep. Adam Anderson championed the Sunshine Genetics Act, the first state-backed genetic disease screening program in the nation. Anderson's son, Drew, died in 2019 from Tay-Sachs disease ...
Epstein paid for novel genetic testing in apparent effort to explore extending life, new emails show
Convicted sex offender Jeffrey Epstein paid for genetic testing in an apparent bid to harness his own genetic material for regenerative medicine – which is aimed at repairing the body by developing ...
About 1 in 4 people suffer from an anxiety disorder at some point in their lives. These include panic disorder with sudden, severe anxiety attacks; generalized anxiety disorder, in which sufferers ...
Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced its contribution to new research leveraging Multiplexed Assays ...
Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics first implemented RNA testing in 2016 as part of a research and ...
Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Ambry Genetics, a leader in clinical genomic ...
Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the completion of its one-millionth DNA/RNA test, underscoring the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results